Ablynx Announces 2012 Full Year Results

Year of Strong Operational and Financial Progress Regulated Information

(firmenpresse) - GHENT, BELGIUM -- (Marketwire) -- 02/27/13 -- (EURONEXT BRUSSELS: ABLX) today announced its consolidated results for 2012, which have been prepared in accordance with IFRS as adopted by the European Union.



First Nanobody®, ALX-0171 (anti-RSV), successfully delivered directly into the lungs using a nebuliser

Second clinical proof-of-concept for Nanobodies achieved with the anti-IL-6R product, ALX-0061, in RA patients

Three pre-clinical candidates selected as part of the Strategic Alliance with Boehringer Ingelheim and FTE payments under that Alliance extended by two years

Boehringer Ingelheim filed a Clinical Trials Application for a Nanobody as part of the Alzheimer's collaboration

Progress in the Merck Serono collaboration with the selection of a second pre-clinical candidate, ALX-0751 in oncology

New partnership signed with Merck & Co for the discovery of Nanobodies targeting a voltage-gated ion channel and an option to a second undisclosed target

Entered into a feasibility study with Algeta to explore the use of Nanobodies in radio-immunotherapy for oncology

Strengthened the Board of Directors with the appointment of two key industry experts (ex-Amgen and ex-GSK)



Revenue growth of 22% to EUR 26.7M (2011: EUR 21.9M)

Cash-in increased by 28% to EUR 36.5M (2011: EUR 28.5M)

Operating expenses decreased by 16% to EUR 56.3M (2011: EUR 66.7M)

Net loss for the year reduced by 35% to EUR 28.5M (2011: EUR 43.9M)

Net cash burn well controlled at just EUR 21.1M

Strong year-end financial position of EUR 62.8M in cash, cash equivalents, restricted cash and short-term investments



Promising 24 week Phase II efficacy and safety results with the anti-IL-6R Nanobody, ALX-0061, in patients with RA

Entered into a research collaboration with Spirogen to evaluate the potential of toxin-Nanobody drug conjugates in cancer

"2012 was an excellent and rewarding year for Ablynx across all areas of our business. We were able to further demonstrate the power and broad applicability of the Nanobody platform, including the opportunity to deliver Nanobodies directly via the pulmonary route, the potential to design best-in-class molecules and the capability to address difficult disease targets in areas where conventional technologies have not yet been successful. The progression of our existing partnerships and the start of new collaborations are a further endorsement of our achievements to date. During the coming year, we expect important new partnering deals and advances in existing collaborations as some of our partnered programmes move into clinical development. We remain committed to building shareholder value."







(1) including EUR 2.7 million restricted cash

Ablynx is a biopharmaceutical company engaged in the discovery and development of Nanobodies®, a novel class of therapeutic proteins based on single-domain antibody fragments, for a range of serious human diseases, including inflammation, haematology, oncology and pulmonary disease. Today, the Company has approximately 25 programmes in the pipeline and five Nanobodies at clinical development stage. Ablynx has on-going research collaborations and significant partnerships with major pharmaceutical companies including Boehringer Ingelheim, Merck Serono, Novartis and Merck & Co. The Company is headquartered in Ghent, Belgium.
More information can be found on .

complete version of the press release



Dr Edwin Moses
Chairman and CEO
t: +32 (0)9 262 00 07
m: +44 (0)7771 954 193 /
+32 (0)473 39 50 68
e:

Marieke Vermeersch
Associate Director Investor Relations
t: +32 (0)9 262 00 82
m: +32 (0)479 49 06 03
e:
Follow us on Twitter (at)AblynxABLX

Mary-Jane Elliott, Amber Bielecka, Claire Dickinson
t: +44 207 920 2330
e:

Weitere Infos zu dieser Pressemeldung:

Themen in dieser Pressemitteilung:


Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: MARKETWIRE
Datum: 27.02.2013 - 07:24 Uhr
Sprache: Deutsch
News-ID 233707
Anzahl Zeichen: 0

contact information:
Town:

GHENT, BELGIUM

Kategorie:

Healthcare

Diese Pressemitteilung wurde bisher 265 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"Ablynx Announces 2012 Full Year Results"
steht unter der journalistisch-redaktionellen Verantwortung von

Ablynx (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).

Publication in Accordance With Article 14 of the Belgian Law of 2 May 2007 Regar ...

GHENT, BELGIUM -- (Marketwired) -- 08/27/13 -- (EURONEXT BRUSSELS: ABLX) today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major shareholdings in issuers whose securities are admitted to tr ...

Ablynx Announces Half-Year Results for 2013 ...

GHENT, BELGIUM -- (Marketwired) -- 08/21/13 -- (EURONEXT BRUSSELS: ABLX) today announced its results for the six-month period ending 30 June 2013, which have been prepared in accordance with the IAS 34 "Interim Financial Reporting" as adop ...

Ablynx Announces Warrant Exercise ...

GHENT, BELGIUM -- (Marketwired) -- 07/23/13 -- (EURONEXT BRUSSELS: ABLX) today announced, in conformity with Title II of the Law of 2 May 2007 and the Royal Decree of 14 February 2008, that an additional 273,913 common shares have been issued by the ...

Alle Meldungen von Ablynx